These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16424347)

  • 21. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
    Bayorh MA; Mann G; Walton M; Eatman D
    Clin Exp Hypertens; 2006 Feb; 28(2):121-32. PubMed ID: 16546838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardioprotective effect of angiotensin II type 1 receptor antagonist associated with bradykinin-endothelial nitric oxide synthase and oxidative stress in Dahl salt-sensitive hypertensive rats.
    Yoshida K; Kobayashi N; Ohno T; Fukushima H; Matsuoka H
    J Hypertens; 2007 Aug; 25(8):1633-42. PubMed ID: 17620960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
    Custodis F; Baumhäkel M; Schlimmer N; List F; Gensch C; Böhm M; Laufs U
    Circulation; 2008 May; 117(18):2377-87. PubMed ID: 18443241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
    Keidar S; Gamliel-Lazarovich A; Kaplan M; Pavlotzky E; Hamoud S; Hayek T; Karry R; Abassi Z
    Circ Res; 2005 Oct; 97(9):946-53. PubMed ID: 16179584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production.
    Shimada K; Hirano E; Kimura T; Fujita M; Kishimoto C
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1039-44. PubMed ID: 22946091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
    Imanishi T; Ikejima H; Tsujioka H; Kuroi A; Kobayashi K; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    Hypertension; 2008 Mar; 51(3):734-41. PubMed ID: 18227404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation.
    Fukuda D; Enomoto S; Nagai R; Sata M
    Biomed Pharmacother; 2009 Dec; 63(10):754-61. PubMed ID: 19304450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
    Onozato ML; Tojo A; Kobayashi N; Goto A; Matsuoka H; Fujita T
    Nephrol Dial Transplant; 2007 May; 22(5):1314-22. PubMed ID: 17324946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unpredictable chronic mild stress promotes atherosclerosis in high cholesterol-fed rabbits.
    Lu XT; Liu YF; Zhang L; Yang RX; Liu XQ; Yan FF; Wang YB; Bai WW; Zhao YX; Jiang F
    Psychosom Med; 2012; 74(6):604-11. PubMed ID: 22753638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor.
    Sherajee SJ; Fujita Y; Rafiq K; Nakano D; Mori H; Masaki T; Hara T; Kohno M; Nishiyama A; Hitomi H
    Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):257-63. PubMed ID: 22173225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valsartan attenuates oxidative stress and NF-κB activation and reduces myocardial apoptosis after ischemia and reperfusion.
    Wu B; Lin R; Dai R; Chen C; Wu H; Hong M
    Eur J Pharmacol; 2013 Apr; 705(1-3):140-7. PubMed ID: 23499691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
    Oumouna-Benachour K; Hans CP; Suzuki Y; Naura A; Datta R; Belmadani S; Fallon K; Woods C; Boulares AH
    Circulation; 2007 May; 115(18):2442-50. PubMed ID: 17438151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice.
    Pöss J; Werner C; Lorenz D; Gensch C; Böhm M; Laufs U
    Basic Res Cardiol; 2010 Nov; 105(6):725-35. PubMed ID: 20857126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long-term effect of angiotensin II type 1a receptor deficiency on hypercholesterolemia-induced atherosclerosis.
    Eto H; Miyata M; Shirasawa T; Akasaki Y; Hamada N; Nagaki A; Orihara K; Biro S; Tei C
    Hypertens Res; 2008 Aug; 31(8):1631-42. PubMed ID: 18971539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice.
    Raz-Pasteur A; Gamliel-Lazarovich A; Coleman R; Keidar S
    J Cardiovasc Pharmacol; 2012 Dec; 60(6):508-12. PubMed ID: 23232789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol.
    Lee JH; Oh GT; Park SY; Choi JH; Park JG; Kim CD; Lee WS; Rhim BY; Shin YW; Hong KW
    J Pharmacol Exp Ther; 2005 May; 313(2):502-9. PubMed ID: 15734902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
    Schäfer N; Lohmann C; Winnik S; van Tits LJ; Miranda MX; Vergopoulos A; Ruschitzka F; Nussberger J; Berger S; Lüscher TF; Verrey F; Matter CM
    Eur Heart J; 2013 Dec; 34(45):3515-24. PubMed ID: 23594590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice.
    Iwai M; Inaba S; Tomono Y; Kanno H; Iwanami J; Mogi M; Horiuchi M
    Hypertens Res; 2008 Jan; 31(1):161-8. PubMed ID: 18360031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-β1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels.
    Jiao B; Wang YS; Cheng YN; Gao JJ; Zhang QZ
    Biosci Trends; 2011 Aug; 5(4):173-81. PubMed ID: 21914953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.